Predictive markers in breast cancer - The present

Histopathology

Volumn 52, Issue 1, 2008, Pages 82-90

  Payne, S J L ^b   Bowen, R L ^b   Jones, J L ^b   Wells, C A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chromogenic in situ hybridization; Fluorescence in situ hybridization; HER 2; Immunohistochemistry; Oestrogen receptor; Progesterone receptor

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ASSAY; BREAST CANCER; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; HORMONAL THERAPY; HUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 37249004281     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02897.x     Document Type: Review

References (44)

1. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res. Treat. 2002 76 27 36.
2. Parl FF, Schmidt BP, Dupont WD, Wagner RK. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984 54 2237 2242.
3. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J. Clin. Oncol. 1988 6 1076 1087.
4. Crowe JP Jr., Gordon NH, Hubay CA et al. Estrogen receptor determination and long term survival of patients with carcinoma of the breast. Surg. Gynecol. Obstet. 1991 173 273 278.
5. Aaltomaa S, Lipponen P, Eskelinen M et al. Hormone receptors as prognostic factors in female breast cancer. Ann. Med. 1991 23 643 648.
6. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J. Clin. Oncol. 2001 19 18 27.
7. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007 9 R6.
8. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J. Natl Cancer Inst. 1998 90 814 823.
9. Nilsson S, Makela S, Treuter E et al. Mechanisms of estrogen action. Physiol. Rev. 2001 81 1535 1565.
10. Watanabe T, Inoue S, Ogawa S et al. Agonistic effect of tamoxifen is dependent on cell type, ERE-promoter context, and estrogen receptor subtype: functional difference between estrogen receptors alpha and beta. Biochem. Biophys. Res. Commun. 1997 236 140 145.
11. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998 54 105 112.
12. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res. Treat. 1998 51 227 238.
13. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 1978 103 1742 1751.
14. Ravdin PM, Green S, Dorr TM et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J. Clin. Oncol. 1992 10 1284 1291.
15. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 2003 21 1973 1979.
16. Fuqua SA, Fitzgerald SD, Chamness GC et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 51 105 109.
17. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 35 1451 1467.
18. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999 17 1474 1481.
19. Leake R, Barnes D, Pinder S et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J. Clin. Pathol. 2000 53 634 635.
20. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990 50 7057 7061.
21. Rhodes A, Jasani B, Balaton AJ et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am. J. Clin. Pathol. 2001 115 44 58.
22. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod. Pathol. 1999 12 827 834.
23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 177 182.
24. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N. Engl. J. Med. 2005 353 1652 1654.
25. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol. 2001 19 2334 2356.
26. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001 344 783 792.
27. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 2006 354 809 820.
28. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005 353 1673 1684.
29. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 369 29 36.
30. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 2006 355 2733 2743.
31. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 2006 354 2103 2111.
32. Konecny GE, Thomssen C, Luck HJ et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J. Natl Cancer Inst. 2004 96 1141 1151.
33. Prowell TM, Armstrong DK. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play? Semin. Oncol. 2006 33 681 687.
34. Dent R, Clemons M. Adjuvant trastuzumab for breast cancer. BMJ 2005 331 1035 1036.
35. Kroese M, Zimmern RL, Pinder SE. HER2 status in breast cancer - an example of pharmacogenetic testing. J. R. Soc. Med. 2007 100 326 329.
36. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 2004 5 63 69.
37. Persons DL, Tubbs RR, Cooley LD et al. HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch. Pathol. Lab. Med. 2006 130 325 331.
38. NHS Breast Screening Programme. Pathology reporting of breast disease. Sheffield, UK : NHS Cancer Screening Programmes and the Royal College of Pathologists, 2005.
39. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J. Natl Cancer Inst. 2002 94 852 854.
40. Dowsett M, Bartlett J, Ellis IO et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 2003 199 418 423.
41. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
42. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. U. S. A. 2003 100 8418 8423.
43. van de Rijn M, Perou CM, Tibshirani R et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 2002 161 1991 1996.
44. Ellis IO, Bartlett J, Dowsett M et al. Best Practice No. 176: updated recommendations for HER2 testing in the UK. J. Clin. Pathol. 2004 57 233 237.